<?xml version='1.0' encoding='utf-8'?>
<document id="27113346"><sentence text="Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib."><entity charOffset="50-59" id="DDI-PubMed.27113346.s1.e0" text="Bosutinib" /></sentence><sentence text="Chronic myeloid leukemia (CML) is a clonal myeloproliferative stem cell disorder" /><sentence text=" Bosutinib is an oral, once-daily SRC/ABL tyrosine kinase inhibitor with very potent inhibitory activity"><entity charOffset="1-10" id="DDI-PubMed.27113346.s3.e0" text="Bosutinib" /><entity charOffset="42-50" id="DDI-PubMed.27113346.s3.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27113346.s3.e0" e2="DDI-PubMed.27113346.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27113346.s3.e0" e2="DDI-PubMed.27113346.s3.e1" /></sentence><sentence text=" Bosutinib is effective against all phases of intolerant or resistant Philadelphia chromosome-positive CML that do not harbor the T315I or V299LABL kinase domain mutations"><entity charOffset="1-10" id="DDI-PubMed.27113346.s4.e0" text="Bosutinib" /></sentence><sentence text=" Peak plasma concentrations of bosutinib occur at 4-6 h following oral administration, and dose-proportional increases in exposure are observed at doses ranging from 200 to 800 mg"><entity charOffset="31-40" id="DDI-PubMed.27113346.s5.e0" text="bosutinib" /></sentence><sentence text=" Absorption of bosutinib increases with food"><entity charOffset="15-24" id="DDI-PubMed.27113346.s6.e0" text="bosutinib" /></sentence><sentence text=" Bosutinib is distributed extensively into the tissues"><entity charOffset="1-10" id="DDI-PubMed.27113346.s7.e0" text="Bosutinib" /></sentence><sentence text=" It is highly plasma protein bound (94 %) and is primarily metabolized in the liver by cytochrome P450 3A4" /><sentence text=" Bosutinib is well tolerated overall and has a unique but manageable toxicity profile"><entity charOffset="1-10" id="DDI-PubMed.27113346.s9.e0" text="Bosutinib" /></sentence><sentence text=" This article provides a review of the available clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction data on bosutinib in healthy subjects, patients with CML, and special populations"><entity charOffset="126-135" id="DDI-PubMed.27113346.s10.e0" text="bosutinib" /></sentence><sentence text="" /></document>